Original Articles
13 September 2022
Vol. 74 No. 2 (2022)
Frequency of ANA/DFS70 autoantibodies in Colombian patients with undifferentiated connective tissue disease
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
1384
Views
777
Downloads
Authors
The objective was to describe the clinical characteristics and the frequency of the ANA/DFS70 autoantibodies in patients affected by undifferentiated connective tissue disease (UCTD) in a tertiary hospital in Colombia. This descriptive cross-sectional study enrolled patients who fulfilled the classification criteria for UCTD. ANAHEp- 2 test and the modified assay for ANA/DFS70 autoantibodies were performed through the indirect immunofluorescence technique. Erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, and the antibodies to anti-extractable nuclear antigens, DNA, phospholipids (IgG, IgM, IgA), and cyclic citrullinated peptide were also evaluated. Fifty-three patients were studied; 42/53 (79%) tested positive for ANA and 5/42 (11.9%) for ANA/DFS70 antibodies with a dense fine speckled fluorescent pattern (AC-2) in ANA HEp-2 test that was confirmed by a modified HEp-2-DFS70 assay. Patients had arthralgia (87%, n=47), non-erosive arthritis (66%, n=34), xerostomia (64%, n=34), xerophthalmia (42%, n=22), and Raynaud’s phenomenon (17%, n=9). Arthralgia, xerophthalmia, xeroderma, and absence of disease evolution to a specific disease over five years were more frequent in patients with a positive result for the anti-DFS70 antibodies. The ANA/DFS70 autoantibodies were more frequent in patients with UCTD compared to other rheumatic diseases for which they were initially evaluated. More studies are required to support the predictive role of this antibody to the absence of progression to a well-defined connective tissue disease.
Altmetrics
Downloads
Download data is not yet available.
Citations
Mosca M, Tani C, Neri C, della Rossa A, Baldini C, Talarico R, et al. Analysis of the evolution to defined connective tissue diseases of patients with “early unidifferentiated connective tissue diseases (UCTD).” Reumatismo. 2011;60(1). DOI: 10.4081/reumatismo.2008.35. DOI: https://doi.org/10.4081/reumatismo.2008.35
Mosca M, Tani C, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a new frontier for rheumatology. Best Practice & Research Clinical Rheumatology. 2007;21(6):1011–23. DOI: 10.1016/j.berh.2007.09.004. DOI: https://doi.org/10.1016/j.berh.2007.09.004
Swaak AJG. Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology. 2001;40(1):89–94. DOI: 10.1093/rheumatology/40.1.89. DOI: https://doi.org/10.1093/rheumatology/40.1.89
Mosca M, Tani C, Neri C, Baldini C, Bombardieri S. Undifferentiated connective tissue diseases (UCTD). Autoimmunity Reviews. 2006;6(1):1–4. DOI: 10.1016/j.autrev.2006.03.004. DOI: https://doi.org/10.1016/j.autrev.2006.03.004
Doria A, Mosca M, Gambari PF, Bombardieri S. Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both? J Rheumatol. 2005;32(2):213–5.
Mosca M, Tani C, Carli L, della Rossa A, Talarico R, Baldini C, et al. Analysis of the evolution of UCTD to defined CTD after a long term follow-up. Clin Exp Rheumatol. 31(3):471.
Danieli MG, Fraticelli P, Franceschini F, Cattaneo R, Farsi A, Passaleva A, et al. Five-year follow-up of 165 Italian patients with undifferentiated connective tissue diseases. Clin Exp Rheumatol. 17(5):585–91.
Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Annals of the Rheumatic Diseases. 2014;73(1):17–23. DOI: 10.1136/annrheumdis-2013-203863. DOI: https://doi.org/10.1136/annrheumdis-2013-203863
Basu A, Sanchez TW, Casiano CA. DFS70/LEDGFp75: An Enigmatic Autoantigen at the Interface between Autoimmunity, AIDS, and Cancer. Front Immunol. 2015;6:116. DOI: 10.3389/fimmu.2015.00116. DOI: https://doi.org/10.3389/fimmu.2015.00116
Infantino M, Meacci F, Grossi V, Manfredi M, Li Gobbi F, Sarzi-Puttini P, et al. The clinical impact of Anti-DFS70 antibodies in undifferentiated connective tissue disease: case reports and a review of the literature. Immunologic Research. 2017;65(1):293–5. DOI: 10.1007/s12026-016-8836-4. DOI: https://doi.org/10.1007/s12026-016-8836-4
Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LEC. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis & Rheumatism. 2011;63(1):191–200. DOI: 10.1002/art.30084. DOI: https://doi.org/10.1002/art.30084
Mahler M, Parker T, Peebles CL, Andrade LE, Swart A, Carbone Y, et al. Anti-DFS70/LEDGF Antibodies Are More Prevalent in Healthy Individuals Compared to Patients with Systemic Autoimmune Rheumatic Diseases. The Journal of Rheumatology. 2012;39(11):2104–10. DOI: 10.3899/jrheum.120598. DOI: https://doi.org/10.3899/jrheum.120598
Romero-Álvarez V, Acero-Molina DA, Beltrán-Ostos A, Bello-Gualteros JM, Romero-Sánchez C. Frecuencia de ANA/DFS70 en familiares de pacientes con artritis reumatoide comparados con pacientes con artritis reumatoide y población sana y su asociación con el estado de salud. Reumatología Clínica. 2021;17(2):67–73. DOI: 10.1016/j.reuma.2019.02.003. DOI: https://doi.org/10.1016/j.reuma.2019.02.003
Arteaga S, Urrego T, Peñaranda L, Londoño A, Cardenas M, Vanegas A, et al. 274 Prevalence of anti-dfs70 antibodies in a colombian cohort: a case-control study. In: Poster Session. Lupus Foundation of America; 2017. p. A125.3-A127. DOI: 10.1136/lupus-2017-000215.274. DOI: https://doi.org/10.1136/lupus-2017-000215.274
Muro Y, Sugiura K, Morita Y, Tomita Y. High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody–positive patients with autoimmune rheumatic disease. Lupus. 2008;17(3):171–6. DOI: 10.1177/0961203307086311. DOI: https://doi.org/10.1177/0961203307086311
Infantino M, Shovman O, Pérez D, Manfredi M, Grossi V, Benucci M, et al. Anti-DFS70 autoantibodies in undifferentiated connective tissue diseases subjects: what’s on the horizon? Rheumatology. 2018;57(7):1293–8. DOI: 10.1093/rheumatology/key012. DOI: https://doi.org/10.1093/rheumatology/key012
Ganapathy V, Casiano CA. Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): What exactly are the autoantibodies trying to tell us? Arthritis & Rheumatism. 2004;50(3):684–8. DOI: 10.1002/art.20095. DOI: https://doi.org/10.1002/art.20095
Vázquez-Del Mercado M, Gómez-Bañuelos E, Navarro-Hernández RE, Pizano-Martinez O, Saldaña-Millán A, Chavarria-Avila E, et al. Detection of autoantibodies to DSF70/LEDGFp75 in Mexican Hispanics using multiple complementary assay platforms. Autoimmunity Highlights. 2017;8(1):1. DOI: 10.1007/s13317-016-0089-7. DOI: https://doi.org/10.1007/s13317-016-0089-7
Albesa R, Sachs U, Infantino M, Manfredi M, Benucci M, Baus Y, et al. Increased prevalence of anti-DFS70 antibodies in young females: experience from a large international multi-center study on blood donors. Clinical Chemistry and Laboratory Medicine (CCLM). 2019;57(7):999–1005. DOI: 10.1515/cclm-2018-1233. DOI: https://doi.org/10.1515/cclm-2018-1233
Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis & Rheumatism. 2004;50(3):892–900. DOI: 10.1002/art.20096. DOI: https://doi.org/10.1002/art.20096
Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol. 17(5):615–20.
Leroy EC, Maricq HR, Bashar Kahaleh M. Undifferentiated connective tissue syndromes. Arthritis & Rheumatism. 1980;23(3):341–3. DOI: 10.1002/art.1780230312. DOI: https://doi.org/10.1002/art.1780230312
Mosca M, Tani C, Bombardieri S. Defining undifferentiated connective tissue diseases: a challenge for rheumatologists. Lupus. 2008;17(4):278–80. DOI: 10.1177/0961203307088004. DOI: https://doi.org/10.1177/0961203307088004
Sabo I. The lanthanic or undifferentiated collagen disease. Hiroshima J Med Sci. 1969;18(4):259–64.
Bodolay E, Csiki Z, Szekanecz Z, Ben T, Kiss E, Zeher M, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol. 21(3):313–20.
Mosca M, Neri R, Bencivelli W, Tavoni A, Bombardieri S. Undifferentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years. J Rheumatol. 2002;29(11):2345–9. DOI: https://doi.org/10.1191/0961203302lu187oa
Alarcón GS, Williams G v, Singer JZ, Steen VD, Clegg DO, Paulus HE, et al. Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease. J Rheumatol. 1991;18(9):1332–9.
Guerrero LF, Rueda JC, Arciniegas R, Rueda JM. Undifferentiated connective tissue disease in a rheumatology center in Cali, Colombia: clinical features of 94 patients followed for a year. Rheumatology International. 2013;33(4):1085–8. DOI: 10.1007/s00296-011-2234-y. DOI: https://doi.org/10.1007/s00296-011-2234-y
Mosca M, Tani C, Vagnani S, Carli L, Bombardieri S. The diagnosis and classification of undifferentiated connective tissue diseases. Journal of Autoimmunity. 2014;48–49:50–2. DOI: 10.1016/j.jaut.2014.01.019. DOI: https://doi.org/10.1016/j.jaut.2014.01.019
Conrad K, Röber N, Andrade LEC, Mahler M. The Clinical Relevance of Anti-DFS70 Autoantibodies. Clinical Reviews in Allergy & Immunology. 2017;52(2):202–16. DOI: 10.1007/s12016-016-8564-5. DOI: https://doi.org/10.1007/s12016-016-8564-5
Gundín S, Irure-Ventura J, Asensio E, Ramos D, Mahler M, Martínez-Taboada V, et al. Measurement of anti-DFS70 antibodies in patients with ANA-associated autoimmune rheumatic diseases suspicion is cost-effective. Autoimmunity Highlights. 2016;7(1):10. DOI: 10.1007/s13317-016-0082-1. DOI: https://doi.org/10.1007/s13317-016-0082-1
How to Cite
Frequency of ANA/DFS70 autoantibodies in Colombian patients with undifferentiated connective tissue disease. (2022). Reumatismo, 74(2). https://doi.org/10.4081/reumatismo.2022.1420
Copyright (c) 2022 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
